Lung Cancer
Volume 70, Issue 2 , Pages 119-128 , November 2010

Maintenance or consolidation therapy in small-cell lung cancer: A systematic review and meta-analysis

  • Antonio Rossi

      Affiliations

    • Division of Medical Oncology, “S.G. Moscati” Hospital, Città Ospedaliera, Contrada Amoretta 8, 83100 Avellino, Italy
    • Corresponding Author InformationCorresponding author. Tel.: +39 0825 203573; fax: +39 0825 203556.
    • ,
  • Marina Chiara Garassino

      Affiliations

    • Oncology Department, “Fatebenefratelli and Oftalmico” Hospital, Milan, Italy
    • ,
  • Michela Cinquini

      Affiliations

    • Laboratory of New Drug Development Strategies, Oncology Department, “Mario Negri” Institute, Milan, Italy
    • ,
  • Paola Sburlati

      Affiliations

    • Oncology Department, “Fatebenefratelli and Oftalmico” Hospital, Milan, Italy
    • ,
  • Massimo Di Maio

      Affiliations

    • Clinical Trials Unit, National Cancer Institute, “G. Pascale” Foundation, Naples, Italy
    • ,
  • Gabriella Farina

      Affiliations

    • Oncology Department, “Fatebenefratelli and Oftalmico” Hospital, Milan, Italy
    • ,
  • Cesare Gridelli

      Affiliations

    • Division of Medical Oncology, “S.G. Moscati” Hospital, Città Ospedaliera, Contrada Amoretta 8, 83100 Avellino, Italy
    • ,
  • Valter Torri

      Affiliations

    • Laboratory of New Drug Development Strategies, Oncology Department, “Mario Negri” Institute, Milan, Italy

Received 9 May 2009 ,Revised 9 September 2009 ,Accepted 1 February 2010.

References 

  1. Elias AD. Small cell lung cancer: state-of-the-art therapy in 1996. Chest. 1997;112(Suppl. 4):251S–258S
  2. Patel AM, Dunn WF, Trastek VF. Staging systems of lung cancer. Mayo Clin Proc. 1993;68:475–482
  3. Samson DJ, Sidenfeld J, Simon GR, Turrisi AT, Bonnell C, Ziegler KM, et al. Evidence for management of small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007;132:314S–323S
  4. Simon GR, Turrisi A. Management of small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007;132:324S–339S
  5. Sorensen M, Felip E. Small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment an follow-up. Ann Oncol. 2009;20(Suppl. 4):iv71–iv72
  6. Bozcuk H, Artac M, Ozdogan M, Savas B. Does maintenance/consolidation chemotherapy have a role in the management of small cell lung cancer (SCLC)?. Cancer. 2005;104:2650–2657
  7. Grossi F, Aita M, Follador A, Defferrari C, Brianti A, Sinaccio G, et al. Sequential, alternating and maintenance/consolidation chemotherapy in advanced non-small cell lung cancer: a review of the literature. Oncologist. 2007;12:451–464
  8. Rinaldi M, Belvedere O, Cauchi C, Defferrari C, Viola G, Grossi F. Maintenance chemotherapy in non-small cell lung cancer. Ann Oncol. 2006;17(Suppl. 2):ii67–ii70
  9. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17:2815–2834
  10. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–1558
  11. Higgins JPT, Green S. Analysing data and undertaking meta-analyses. Cochrane handbook for systematic reviews of interventions, version 5.0.1 [updated September 2008]. The Cochrane Collaboration; 2008;
  12. Cochrane Collaboration. RevMan user guide. 2004;Available from URL: http://www.ccims.net/download/revman/Documentation/User%20guide.pdf [Accessed 21 Dec 2007]
  13. Jadad AR, Moore RA, Carol D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials. 1996;17:1–12
  14. Spiro SG, Souhami RL, Geddes DM, Ash CM, Quinn H, Harper PG, et al. Duration of chemotherapy in small cell lung cancer: a Cancer Research Campaign Trial. Br J Cancer. 1989;59:578–583
  15. Zarogoulidis K, Ziogas E, Papagiannis A, Charitopoulos K, Dimitriadis K, Economides D, et al. Interferon alpha-2a and combined chemotherapy as first line treatment in SCLC patients: a randomised trial. Lung Cancer. 1996;15:197–215
  16. Routsalainen TM, Halme M, Tamminen K, Szopinski J, Niiranen A, Pyrhonen S, et al. Concomitant chemotherapy and IFN-α for small cell lung cancer: a randomized multicenter phase III study. J Interferon Cytokine Res. 1999;19:253–259
  17. Lee SM, Woll PJ, Rudd R, Ferry D, O’Brien M, Middleton G, et al. Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized, double-blind, placebo-controlled trial. J Natl Cancer Inst. 2009;101:1049–1057
  18. Einhorn LH, Crawford J, Birch R, Omura G, Johnson DH, Greco FA. Cisplatin plus etoposide consolidation following cyclophosphamide, doxorubicin and vincristine in limited small-cell lung cancer. J Clin Oncol. 1984;6:451–456
  19. Tummarello D, Graziano F, Mari D, Cetto G, Pasini F, Santo A, et al. Small cell lung cancer (SCLC): a randomized trial of cyclophosphamide, adryamicin, vincristine plus etoposide (CAV-E) or teniposide (CAV-T) as induction treatment, follone in complete responders by alfa-interferon or no treatment, as maintenance therapy. Anticancer Res. 1994;14:2221–2228
  20. Mattson K, Niiranen A, Ruotsalainen T, Maasilta P, Halme M, Pyrhonen S, et al. Interferon maintenance therapy for small cell lung cancer: improvement in long-term survival. J Interferon Cytokine Res. 1997;17:103–107
  21. Maurer LH, Tulloh M, Weiss RB, Blom J, Leone L, Glidewell O, et al. A randomized combined modality trial in small cell carcinoma of the lung. Comparison of combination chemotherapy-radiation therapy versus cyclophosphamide-radiation therapy effects of maintenance chemotherapy and prophylactic whole brain irradiation. Cancer. 1980;45:30–39
  22. Rigas JR, Denham CA, Rinaldi D, Moore T, Smith JW, Winston RD, et al. Adjuvant target therapy in unresectable lung cancer: the results of two randomized placebo-controlled trials of BAY 12-9566, a matrix metalloproteinase inhibitor (MMPI). Lung Cancer. 2003;41(Suppl. 2):S34;[Abstr O-107]
  23. Broder LE, Sridhar KS, Selawry OS, Charyulu KN, Rao RK, Saldana MJ, et al. A randomized clinical trial in bronchogenic small-cell carcinoma evaluating alternating maintenance therapy of vincristine, adryamicin, procarbazine, and etoposide (VAPE) with cyclophosphamide, CCNU, and methotrexate (CCM) versus CCM maintenance alone in complete responders following VAPE induction and late intensification. Am J Clin Oncol. 1994;17:527–537
  24. Pandya KJ, Dahlberg S, Hidalgo M, Cohen RB, Lee MW, Schiller JH, et al. A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: a trial of the Eastern Cooperative Oncology Group (E1500). A preliminary report. J Thorac Oncol. 2007;2:1036–1041
  25. Pujol JL, Gibney DJ, Su JQ, Maksymiuk AW, Jett JR. Immune response induced in small-cell lung cancer by maintenance therapy with interferon-γ. J Natl Cancer Inst. 1993;85:1844–1850
  26. Cullen M, Morgan D, Gregory W, Robinson M, Cox D, McGivern D, et al. Maintenance chemotherapy for anaplastic small cell carcinoma of the bronchus: a randomized, controlled trial. Cancer Chemother Pharmacol. 1986;17:157–160
  27. Anonymous . Controlled trial of twelve versus six courses of chemotherapy in the treatment of small-cell lung cancer. Br J Cancer. 1989;59:584–590
  28. Byrne MJ, van Hazel G, Trotter J, Cameron F, Shepherd J, Cassidy B, et al. Maintenance chemotherapy in limited small cell lung cancer: a randomised controlled clinical trial. Br J Cancer. 1989;60:413–418
  29. Ettinger DS, Finkelstein DM, Abeloff MD, Ruckdeschel JC, Aisner SC, Eggleston JC A phase III study of the Eastern Cooperative Oncology Group. A randomized comparison of standard chemotherapy versus alternating chemotherapy and maintenance versus no maintenance therapy for extensive stage small-cell lung cancer. J Clin Oncol. 1990;8:230–240
  30. Giaccone G, Dalesio O, McVie GJ, Kirkpatrick A, Postmus PE, Burghouts JThM , et al. Maintenance chemotherapy in small-cell lung cancer: long-term results of a randomized trials. J Clin Oncol. 1993;11:1230–1240
  31. Johnson DH, Bass D, Einhorn LH, Crawford J, Perez CA, Bartolucci A, et al. Combination chemotherapy with or without thoracic radiotherapy in limited-stage small-cell lung cancer. J Clin Oncol. 1993;11:1223–1229
  32. Beith JM, Clarke SJ, Woods RL, Bell DR, Levi JA. Long-term follow-up of a randomised trial of combined chemoradiotherapy induction treatment, with and without maintenance chemotherapy in patients with small cell carcinoma of the lung. Eur J Cancer. 1996;32A:438–443
  33. Sculier JP, Paesmans M, Bureau G, Giner V, Lecomte J, Michel J, et al. Randomized trial comparing induction chemotherapy versus induction chemotherapy followed by maintenance chemotherapy in small-cell lung cancer. J Clin Oncol. 1996;14:2337–2344
  34. Schiller JH, Adak S, Cella D, DeVore FR, Johnson DH. Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593—a phase III trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2001;19:2114–2122
  35. Hanna NH, Sandler AB, Loehrer PJ, Ansari R, Jung SH, Lane K, et al. Maintenance daily oral etoposide versus no further therapy following induction chemotherapy with etoposide plus ifosfamide plus cisplatin in extensive small-cell lung cancer: a Hoosier Oncology Group randomized study. Ann Oncol. 2002;13:95–102
  36. Han JY, Kim HT, Lim KY, Yoon SJ, Lee DH, Lee JS. Randomized phase II study of maintenance irinotecan therapy versus observation following induction chemotherapy with irinotecan and cisplatin in extensive disease small cell lung cancer. J Thorac Oncol. 2008;3:1039–1045
  37. Mattson K, Niiranen A, Pyrhonen S, Holsti LR, Holsti P, Kumpulainen E, et al. Natural interferon alfa as maintenance therapy for small cell lung cancer. Eur J Cancer. 1992;28A:1387–1391
  38. Kelly K, Crowley JJ, Bunn PA, Hazuka MB, Beasley K, Upchurch C, et al. Role of recombinant interferon alfa-2a maintenance in patients with limited-stage small-cell lung cancer responding to concurrent chemoradiation: a Southwest Oncology Group Study. J Clin Oncol. 1995;13:2924–2930
  39. Tummarello D, Mari D, Graziano F, Isidori P, Cetto G, Pasini F, et al. A randomized, controlled phase III study of cyclophosphamide, doxorubicin, and vincristine with etoposide (CAV-E) or teniposide (CAV-T), followed by recombinant interferon-α maintenance therapy or observation, in small cell lung carcinoma patients with complete responses. Cancer. 1997;80:2222–2229
  40. Lebeau B, De La Salmoniere P, Ozenne G, Blanchon F, Leclerc P, Coertmeur D, et al. αInterferon (αIFN) as maintenance therapy for small cell lung cancer (SCLC). Proc Am Soc Clin Oncol. 1999;18:475a;[Abstr. 1832]
  41. Jett JR, Maksymiuk AW, Su JQ, Mailliard JA, Krook JE, Tschetter LK, et al. Phase III trial of recombinant interferon gamma in complete responders with small cell lung cancer. J Clin Oncol. 1994;12:2321–2326
  42. van Zandwijk N, Groen HJM, Postmus PE, Burghouts JTM, ten Velde GPM, Ardizzoni A, et al. Role of recombinant interferon-gamma maintenance in responding patients with small cell lung cancer. Eur J Cancer. 1997;33:1759–1766
  43. Shepherd FA, Giaccone G, Seymour L, Debruyne C, Bezjak A, Hirsh V, et al. Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol. 2002;20:4434–4439
  44. Giaccone G, Debruyne C, Felip E, Chapman PB, Grant SC, Millward M, et al. Phase III study of adjuvant vaccination with Bec2/Bacille Calmette-Guerin in responding patients with limited-disease small cell lung cancer (European Organization for Research and Treatment of Cancer 08971-08971B; Silva Study). J Clin Oncol. 2005;23:6854–6864
  45. Pujol JL, Breton JL, Gervais R, Tanguy ML, Quoix E, David P, et al. Phase III double-blind, placebo-controlled study of thalidomide in extensive-disease small-cell lung cancer after response to chemotherapy: an Intergroup Study FNCLCC cleo04–IFCT 00-01. J Clin Oncol. 2007;25:3945–3951
  46. Arnold AM, Seymour L, Smylie M, Ding K, Ung Y, Findlay B, et al. Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20. J Clin Oncol. 2007;25:4278–4284
  47. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MD. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16
  48. Sculier JP, Berghmans T, Castaigne C, Luce S, Sotiriou C, Vermylen P, et al. Maintenance chemotherapy for small cell lung cancer: a critical review of the literature. Lung Cancer. 1998;19:141–151

PII: S0169-5002(10)00066-8

doi: 10.1016/j.lungcan.2010.02.001

Lung Cancer
Volume 70, Issue 2 , Pages 119-128 , November 2010

Article Tools

* Image Usage & Resolution